In a world where scientific innovation is redefining the future of medicine, Felix Oyelami and Folake Oyelami, two Nigerian researchers bound by common ancestry, vision, and a shared loss to cancer are combining their expertise to challenge some of the deadliest diseases plaguing both Nigeria and the global south. Their work, grounded in cancer biology, immunology, and public health innovation, is not only rewriting our understanding of tumor resistance but also redefining how collaborative African science can solve global health crises.
Cancer remains one of Nigeria’s most devastating health challenges. It has become one of the most silent yet ruthless killers in Nigeria, claiming lives across all walks of life, including some of the nation’s most influential figures. A few noteworthy mentions of those lost to this devastating disease includes Professor Dora Akunyili, a former Director-General of the NAFDAC, and Ethel Ekpe Aderemi, a beloved Nollywood actress. Their deaths are not just personal tragedies but national losses, highlighting the urgent need for Nigeria to confront its growing cancer crisis. Each year, over 72,000 Nigerians die from the disease, many without access to adequate screening, treatment, or palliative care.
For Felix and Folake, this isn’t just data, it’s personal. After losing multiple loved ones to cancer, they have dedicated their careers to unraveling the mechanisms of tumor development and identifying actionable paths to better diagnosis, treatment, and prevention.
Felix Oyelami, a PhD candidate in Toxicology and Cancer Biology at the University of Kentucky, is at the forefront of translational cancer research. His current investigations focus on ferroptosis, an iron-dependent form of regulated cell death that has shown remarkable promise in targeting treatment-resistant cancers such as triple-negative breast cancer (TNBC), and melanoma, two of the most aggressive and under-researched cancers in Nigeria and Africa at large.
Felix’s expertise lies in the tumor microenvironment, metabolic reprogramming, and immune checkpoint modulation. His unique strength is blending wet-lab science with bioinformatics, mining large datasets (from GEO, TCGA, and others) to reveal novel gene targets and therapeutic vulnerabilities. One of his NIH-supported projects focuses on improving immunotherapy in melanoma by enhancing T-cell cytotoxicity and modulating immune escape pathways. Through advanced techniques such as siRNA knockdown, Western blotting, confocal microscopy, and in vivo tumor modeling, Felix is building a blueprint for personalized, accessible cancer therapy.
Folake Oyelami on the other hand is a Microbiologist and Immunologist in training at the University of Ibadan, who is bringing a frontline perspective to their scientific partnership. With experience at the World Health Organization (WHO) and UNICEF subsidiaries in Nigeria, she has led data audits across healthcare facilities, helped shape immunization policy, and delivered medical outreach programs in underserved communities. Her academic focus is tumor immunology and host–pathogen interactions, making her work crucial in an era where infectious and noncommunicable diseases increasingly intersect.
Folake’s skills bridge laboratory and community. She has performed ELISA-based diagnostics on febrile patients, contributed to dengue virus detection protocols, and led rural health awareness campaigns. More recently, she has joined Felix in applying bioinformatic analysis to understand ferroptosis resistance in cancer. Their joint research explores how targeting PGK1, a key enzyme in glycolysis, can sensitize breast cancer cells to ferroptosis, a novel therapeutic avenue with far-reaching clinical potential.
Their co-authored abstract, “Targeting PGK1 to Enhance Ferroptosis in Breast Cancer,” was accepted and presented at the American Association for Cancer Research (AACR) Annual Meeting, placing them on the global map of cancer innovation.
Felix and Folake’s work is not only scientifically significant, it’s systemically urgent. In Nigeria, where late-stage cancer diagnoses are the norm and treatment options are limited or unaffordable, their approach could offer low-cost, targeted therapies that are both scalable and adaptable to the African context. Their shared goal is to decentralize access to precision medicine, ensuring that breakthroughs made in the lab translate to lives saved on the ground.
Together, they represent a comprehensive model of cancer control: while Felix targets molecular and immune resistance from the lab bench, Folake strengthens the diagnostic and immunological pipeline in real-world health systems. Their synergy demonstrates how a sibling team can unite scientific rigor with public health foresight.
Their journey is also a profound message to national policymakers: Nigeria must act to retain its brightest scientific minds. The loss of highly skilled researchers to the diaspora is not just a personal tragedy, it is a national emergency. Felix and Folake represent the kind of talent that can transform Nigeria’s healthcare system from within, but only if given the opportunity.
“We want to build here. We want to save lives here. But we need the support to do so,” says Felix.
For Nigeria to fully harness the potential of researchers like them, bold investment in local scientific infrastructure is essential. This includes funding for cancer research, better-equipped laboratories, data science hubs, and a national framework that supports young researchers. Their proposed roadmap includes establishing a bioinformatics and cancer modeling hub, expanding research collaborations, and mentoring a new generation of scientists equipped to tackle Nigeria’s most urgent health challenges.
The Oyelamis are more than scientists, they are solution architects. Their commitment is transcontinental, their mission deeply personal. In their hands, cancer research is not an academic abstraction, but a moral obligation. They are working to build a world where cancer is caught early, treated effectively, and prevented holistically, in Nigeria, across Africa, and around the globe.
Felix and Folake Oyelami are rewriting the story of African science, and proving that with vision, determination, and the right national support, homegrown researchers can drive global health breakthroughs.